The in vivo anti-tumor efficacy of RGD-TRAIL and RGD-TRAIL-ELP was evaluated in the COLO-205 tumor-bearing mice (Fig. 7 and Supplementary Fig. S6). Here, NR5A1 is linked to neoplasm.